ArticleAnemia2025
Early Haematologic Response to Oral Iron Treatment in Adults With Moderate Iron-Deficiency Anaemia.
Article in Anemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04309669 (Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identifying early response to oral iron supplementation in anaemic patients is key. This study aims to assess the onset-of-action of oral liquid solution of ferrous gluconate, copper and manganese gluconate in adults with moderate iron deficiency anaemia. Methods: This prospective, open-label study was conducted in France, Bulgaria and Kenya. All patients received 150 mg of oral ferrous gluconate/day for 12 weeks. Eleven blood samples were taken at Day 7 and at Days 0, 3, 5, 7, 10, 14, 21, 28, 56 and 84. The primary endpoint was to assess treatment duration required to observe a +0.5 g/dL haemoglobin (Hb) level increase. Results: Ninety-five moderately anaemic patients were included in the analysis. Hb increase ≥ 0.5 g/dL was observed within 9-10 days of treatment (0.51 g/dL at Day 10, 95% CI: 0.45-0.57 and Conclusion: This study demonstrates for the first time the rapid onset-of-action of oral liquid solution of ferrous gluconate and confirms its good tolerability. Trial Registration: ClinicalTrials.gov identifier: NCT04309669.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.